Microbot Medical Stock Piotroski F Score
MBOT Stock | USD 0.94 0.01 1.56% |
Microbot | Piotroski F Score |
At this time, it appears that Microbot Medical's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
Current Return On Assets | Negative | Focus |
Change in Return on Assets | Increased | Focus |
Cash Flow Return on Assets | Negative | Focus |
Current Quality of Earnings (accrual) | Improving | Focus |
Asset Turnover Growth | Decrease | Focus |
Current Ratio Change | Decrease | Focus |
Long Term Debt Over Assets Change | N/A | Focus |
Change In Outstending Shares | Increase | Focus |
Change in Gross Margin | No Change | Focus |
Microbot Medical Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Microbot Medical is to make sure Microbot is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Microbot Medical's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Microbot Medical's financial numbers are properly reported.
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Asset Turnover | 0.006 | 0.0063 |
|
| |||||
Total Current Liabilities | 4.8 M | 3.8 M |
|
| |||||
Non Current Liabilities Total | 38 K | 40 K |
|
| |||||
Total Assets | 7.9 M | 8.3 M |
|
| |||||
Total Current Assets | 7.5 M | 7.9 M |
|
|
Microbot Medical F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Microbot Medical's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Microbot Medical in a much-optimized way.
Click cells to compare fundamentals
About Microbot Medical Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
Microbot Medical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Microbot Medical from analyzing Microbot Medical's financial statements. These drivers represent accounts that assess Microbot Medical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Microbot Medical's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 43.4M | 49.0M | 53.3M | 21.9M | 16.7M | 15.9M | |
Enterprise Value | 15.5M | 30.2M | 40.5M | 19.9M | 14.4M | 28.5M |
About Microbot Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Microbot Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Microbot Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Microbot Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Microbot Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Microbot Medical's short interest history, or implied volatility extrapolated from Microbot Medical options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Microbot Medical Altman Z Score, Microbot Medical Correlation, Microbot Medical Valuation, as well as analyze Microbot Medical Alpha and Beta and Microbot Medical Hype Analysis. For more information on how to buy Microbot Stock please use our How to Invest in Microbot Medical guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Microbot Stock analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Stocks Directory Find actively traded stocks across global markets |
Is Microbot Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Microbot Medical. If investors know Microbot will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Microbot Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Return On Assets (0.69) | Return On Equity (1.82) |
The market value of Microbot Medical is measured differently than its book value, which is the value of Microbot that is recorded on the company's balance sheet. Investors also form their own opinion of Microbot Medical's value that differs from its market value or its book value, called intrinsic value, which is Microbot Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Microbot Medical's market value can be influenced by many factors that don't directly affect Microbot Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Microbot Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Microbot Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Microbot Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.